US CDC alerts healthcare providers of increase in dengue cases
Adds details in paragraphs 3,4, background throughout
June 25 (Reuters) -The U.S. Centers for Disease Control and Prevention issued an advisory on Tuesday alerting healthcare providers about an increased risk of dengue virus infections in the United States.
Cases of the mosquito-borne viral illness have touched a record high in the Americas this year, the agency said, echoing a similar statement from the World Health Organization last month.
The number of dengue cases reported in the Americas exceeded 9.7 million during the period between January 1 and June 24, twice as many as in all of 2023, the CDC said, adding that a higher-than-expected number of cases have been identified among U.S. travelers.
The agency urged healthcare providers to adopt steps such as promotion of preventive measures, appropriate diagnostic tests and timely reporting of dengue cases to public health authorities, among others, to contain the spread of the infection.
Last month, the WHO "prequalified" Takeda Pharmaceuticals' 4502.T dengue vaccine Qdenga, making it eligible for procurement by United Nations agencies such as UNICEF and Pan American Health Organization.
Qdenga is approved in the European Union and in Indonesia, Thailand, Argentina and Brazil, among others.
French drugmaker Sanofi's SASY.PA Dengvaxia is also approved in several countries in the Americas, the EU and Asia.
Dengue, transmitted through bites of infected Aedes species mosquito vectors, causes symptoms including fever, headaches, vomiting, skin rashes, as well as muscle and joint pain. In some cases, it can cause a more severe hemorrhagic fever, resulting in bleeding that can lead to death.
Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
